🚨 SAFFRON: A double survival win after osimertinib resistance!
Concomitantly published in NEJM at #ESMO26!
Phase III | EGFR-mutant, MET-high NSCLC
Osimertinib + savolitinib vs chemotherapy:
📈 PFS: 7.6 vs 5.4 months (HR 0.55; p<0.001)
🔥 OS: 17.8 vs 12.9 months (HR 0.68; p=0.01)
🎯 ORR: 51% vs 27%
💡 Verdict: MET-driven resistance is actionable. Rebiopsy after osimertinib progression could unlock a survival-improving targeted option!
@myesmo @ESMO_open @NEJM @ASCO @oncoalert @nicogirardcurie
Full paper link in comment below ⬇️
20 浏览 · 0 赞 · 0 转发 · 1 回复
🚨 SAFFRON Phase III: Targeted therapy beats chemotherapy AND improves survival! In EGFR-mutant, MET-overexpressed/amplified NSCLC progressing after osimertinib: Osimertinib + savolitinib vs platinum–pemetrexed (n=338) 📊 PFS: 7.6 vs 5.4 months (HR 0.55; p<0.001) 🔥 OS: 17.8 vs 12.9 months (HR 0.68; p=0.010) ⚠️ Grade ≥3 treatment-related AEs: 40% vs 52%. Verdict: A new biomarker-selected, chemotherapy-free option with demonstrated OS benefit after osimertinib resistance. #ESMO26 #LungCancer @my_esmo @ESMO_open @ASCO @oncoalert在 X 查看被引用的帖子
- Dr Rishabh Jain@DrRishabhOnco
Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy | New England Journal of Medicine https://www.nejm.org/doi/full/10.1056/NEJMoa2611335?query=featured_home
来源：Dr Rishabh Jain · x.com